vs
AVANOS MEDICAL, INC.（AVNS）与捷迈邦美（ZBH）财务数据对比。点击上方公司名可切换其他公司
捷迈邦美的季度营收约是AVANOS MEDICAL, INC.的12.4倍（$2.2B vs $180.9M）。捷迈邦美净利率更高（6.2% vs -0.7%，领先6.9%）。捷迈邦美同比增速更快（10.9% vs 0.7%）。捷迈邦美自由现金流更多（$442.6M vs $21.3M）。过去两年捷迈邦美的营收复合增速更高（9.0% vs 4.4%）
Avanos Medical是一家医疗科技企业，专注于研发生产临床医疗设备，核心业务围绕疼痛管理与慢性护理两大板块展开，致力于帮助患者加快康复、预防感染，同时减少临床治疗中阿片类药物的使用。
捷迈邦美是一家美国上市的医疗设备企业，1927年成立，最初以生产铝制夹板为核心业务，总部设于印第安纳州华沙市，是当地医疗设备产业集群的核心成员，在全球骨科医疗器械领域拥有较高知名度。
AVNS vs ZBH — 直观对比
营收规模更大
ZBH
是对方的12.4倍
$180.9M
营收增速更快
ZBH
高出10.2%
0.7%
净利率更高
ZBH
高出6.9%
-0.7%
自由现金流更多
ZBH
多$421.3M
$21.3M
两年增速更快
ZBH
近两年复合增速
4.4%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $180.9M | $2.2B |
| 净利润 | $-1.3M | $139.4M |
| 毛利率 | 47.5% | 64.7% |
| 营业利润率 | 1.4% | 6.9% |
| 净利率 | -0.7% | 6.2% |
| 营收同比 | 0.7% | 10.9% |
| 净利润同比 | 99.7% | -41.8% |
| 每股收益（稀释后） | $-0.02 | $0.71 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVNSZBH
| Q4 25 | $180.9M | $2.2B | ||
| Q3 25 | $177.8M | $2.0B | ||
| Q2 25 | $175.0M | $2.1B | ||
| Q1 25 | $167.5M | $1.9B | ||
| Q4 24 | $179.6M | $2.0B | ||
| Q3 24 | $170.4M | $1.8B | ||
| Q2 24 | $171.7M | $1.9B | ||
| Q1 24 | $166.1M | $1.9B |
净利润AVNSZBH
| Q4 25 | $-1.3M | $139.4M | ||
| Q3 25 | $-1.4M | $230.9M | ||
| Q2 25 | $-76.8M | $152.8M | ||
| Q1 25 | $6.6M | $182.0M | ||
| Q4 24 | $-397.3M | $239.5M | ||
| Q3 24 | $4.3M | $249.1M | ||
| Q2 24 | $1.8M | $242.8M | ||
| Q1 24 | $-900.0K | $172.4M |
毛利率AVNSZBH
| Q4 25 | 47.5% | 64.7% | ||
| Q3 25 | 48.4% | 72.1% | ||
| Q2 25 | 52.6% | 71.5% | ||
| Q1 25 | 53.6% | 71.2% | ||
| Q4 24 | 54.6% | 71.0% | ||
| Q3 24 | 54.5% | 70.5% | ||
| Q2 24 | 55.7% | 71.5% | ||
| Q1 24 | 57.1% | 72.9% |
营业利润率AVNSZBH
| Q4 25 | 1.4% | 6.9% | ||
| Q3 25 | 0.1% | 17.6% | ||
| Q2 25 | -42.6% | 14.4% | ||
| Q1 25 | 6.1% | 15.3% | ||
| Q4 24 | -233.0% | 19.2% | ||
| Q3 24 | 7.0% | 15.3% | ||
| Q2 24 | 3.7% | 18.1% | ||
| Q1 24 | 2.4% | 14.1% |
净利率AVNSZBH
| Q4 25 | -0.7% | 6.2% | ||
| Q3 25 | -0.8% | 11.5% | ||
| Q2 25 | -43.9% | 7.4% | ||
| Q1 25 | 3.9% | 9.5% | ||
| Q4 24 | -221.2% | 11.8% | ||
| Q3 24 | 2.5% | 13.7% | ||
| Q2 24 | 1.0% | 12.5% | ||
| Q1 24 | -0.5% | 9.1% |
每股收益（稀释后）AVNSZBH
| Q4 25 | $-0.02 | $0.71 | ||
| Q3 25 | $-0.03 | $1.16 | ||
| Q2 25 | $-1.66 | $0.77 | ||
| Q1 25 | $0.14 | $0.91 | ||
| Q4 24 | $-8.64 | $1.18 | ||
| Q3 24 | $0.09 | $1.23 | ||
| Q2 24 | $0.04 | $1.18 | ||
| Q1 24 | $-0.02 | $0.84 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $89.8M | $591.9M |
| 总债务越低越好 | $90.3M | — |
| 股东权益账面价值 | $778.2M | $12.7B |
| 总资产 | $1.1B | $23.1B |
| 负债/权益比越低杠杆越低 | 0.12× | — |
8季度趋势，按日历期对齐
现金及短期投资AVNSZBH
| Q4 25 | $89.8M | $591.9M | ||
| Q3 25 | $70.5M | $1.3B | ||
| Q2 25 | $90.3M | $556.9M | ||
| Q1 25 | $97.0M | $1.4B | ||
| Q4 24 | $107.7M | $525.5M | ||
| Q3 24 | $89.0M | $569.0M | ||
| Q2 24 | $92.2M | $420.1M | ||
| Q1 24 | $75.8M | $393.0M |
总债务AVNSZBH
| Q4 25 | $90.3M | — | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $95.7M | — | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $125.3M | — | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — | ||
| Q1 24 | $167.2M | — |
股东权益AVNSZBH
| Q4 25 | $778.2M | $12.7B | ||
| Q3 25 | $778.0M | $12.8B | ||
| Q2 25 | $776.3M | $12.5B | ||
| Q1 25 | $839.4M | $12.4B | ||
| Q4 24 | $828.5M | $12.5B | ||
| Q3 24 | $1.2B | $12.4B | ||
| Q2 24 | $1.2B | $12.7B | ||
| Q1 24 | $1.2B | $12.6B |
总资产AVNSZBH
| Q4 25 | $1.1B | $23.1B | ||
| Q3 25 | $1.1B | $23.5B | ||
| Q2 25 | $1.0B | $22.9B | ||
| Q1 25 | $1.1B | $22.2B | ||
| Q4 24 | $1.2B | $21.4B | ||
| Q3 24 | $1.7B | $21.7B | ||
| Q2 24 | $1.7B | $21.5B | ||
| Q1 24 | $1.7B | $21.5B |
负债/权益比AVNSZBH
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $28.2M | $517.4M |
| 自由现金流经营现金流 - 资本支出 | $21.3M | $442.6M |
| 自由现金流率自由现金流/营收 | 11.8% | 19.7% |
| 资本支出强度资本支出/营收 | 3.8% | 3.3% |
| 现金转化率经营现金流/净利润 | — | 3.71× |
| 过去12个月自由现金流最近4个季度 | $43.1M | $1.5B |
8季度趋势，按日历期对齐
经营现金流AVNSZBH
| Q4 25 | $28.2M | $517.4M | ||
| Q3 25 | $14.0M | $418.7M | ||
| Q2 25 | $6.8M | $378.2M | ||
| Q1 25 | $25.7M | $382.8M | ||
| Q4 24 | $57.9M | $506.3M | ||
| Q3 24 | $23.0M | $395.7M | ||
| Q2 24 | $27.8M | $369.4M | ||
| Q1 24 | $-8.0M | $228.0M |
自由现金流AVNSZBH
| Q4 25 | $21.3M | $442.6M | ||
| Q3 25 | $7.0M | $363.7M | ||
| Q2 25 | $-4.2M | $328.1M | ||
| Q1 25 | $19.0M | $338.2M | ||
| Q4 24 | $53.1M | $454.8M | ||
| Q3 24 | $20.0M | $351.2M | ||
| Q2 24 | $21.9M | $316.7M | ||
| Q1 24 | $-12.1M | $172.9M |
自由现金流率AVNSZBH
| Q4 25 | 11.8% | 19.7% | ||
| Q3 25 | 3.9% | 18.2% | ||
| Q2 25 | -2.4% | 15.8% | ||
| Q1 25 | 11.3% | 17.7% | ||
| Q4 24 | 29.6% | 22.5% | ||
| Q3 24 | 11.7% | 19.3% | ||
| Q2 24 | 12.8% | 16.3% | ||
| Q1 24 | -7.3% | 9.2% |
资本支出强度AVNSZBH
| Q4 25 | 3.8% | 3.3% | ||
| Q3 25 | 3.9% | 2.7% | ||
| Q2 25 | 6.3% | 2.4% | ||
| Q1 25 | 4.0% | 2.3% | ||
| Q4 24 | 2.7% | 2.5% | ||
| Q3 24 | 1.8% | 2.4% | ||
| Q2 24 | 3.4% | 2.7% | ||
| Q1 24 | 2.5% | 2.9% |
现金转化率AVNSZBH
| Q4 25 | — | 3.71× | ||
| Q3 25 | — | 1.81× | ||
| Q2 25 | — | 2.48× | ||
| Q1 25 | 3.89× | 2.10× | ||
| Q4 24 | — | 2.11× | ||
| Q3 24 | 5.35× | 1.59× | ||
| Q2 24 | 15.44× | 1.52× | ||
| Q1 24 | — | 1.32× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
ZBH
| Knees | $911.0M | 41% |
| SET | $587.6M | 26% |
| Hips | $555.4M | 25% |
| Technology And Data Bone Cement And Surgical | $189.8M | 8% |
